

Table S1. Solicited Local Adverse Events after the Booster Dosing

	Group A: Two Prior Doses of MVC-COV1901				Group B: Three Prior Doses of MVC-COV1901			
	MVC-COV1901 (15 mcg) (N = 15), n (%)	MVC-COV1901 (15 mcg, Beta) (N = 15), n (%)	MVC-COV1901 (25 mcg, Beta) (N = 15), n (%)	All Participants (N = 45), n (%)	MVC-COV1901 (15 mcg) (N = 21), n (%)	MVC-COV1901 (15 mcg, Beta) (N = 21), n (%)	MVC-COV1901 (25 mcg, Beta) (N = 20), n (%)	All Participants (N = 62), n (%)
Any Solicited Local AEs	10 (66.7)	11 (73.3)	9 (60.0)	30 (66.7)	13 (61.9)	12 (57.1)	14 (70.0)	39 (62.9)
Grade 1	10 (66.7)	11 (73.3)	8 (53.3)	29 (64.4)	13 (61.9)	11 (52.4)	14 (70.0)	38 (61.3)
Grade 2	0	0	1 (6.7)	1 (2.2)	0	1 (4.8)	0	1 (1.6)
Grade 3	0	0	0	0	0	0	0	0
Pain/Tenderness	10 (66.7)	11 (73.3)	9 (60.0)	30 (66.7)	13 (61.9)	12 (57.1)	14 (70.0)	39 (62.9)
Grade 1	10 (66.7)	11 (73.3)	8 (53.3)	29 (64.4)	13 (61.9)	11 (52.4)	14 (70.0)	38 (61.3)
Grade 2	0	0	1 (6.7)	1 (2.2)	0	1 (4.8)	0	1 (1.6)
Grade 3	0	0	0	0	0	0	0	0
Erythema/Redness	1 (6.7)	0	1 (6.7)	2 (4.4)	0	0	0	0
Grade 1	1 (6.7)	0	1 (6.7)	2 (4.4)	0	0	0	0
Grade 2	0	0	0	0	0	0	0	0
Grade 3	0	0	0	0	0	0	0	0
Induration/Swelling	2 (13.3)	0	3 (20.0)	5 (11.1)	0	1 (4.8)	1 (5.0)	2 (3.2)
Grade 1	2 (13.3)	0	3 (20.0)	5 (11.1)	0	0	1 (5.0)	1 (1.6)
Grade 2	0	0	0	0	0	1 (4.8)	0	1 (1.6)
Grade 3	0	0	0	0	0	0	0	0

Abbreviations: N = number of subjects in the population; n = number of subjects in the specific category. % = percentage of subjects with N as the denominator.

Table S2. Solicited Systemic Adverse Events after the Booster Dosing

	Group A: Two Prior Doses of MVC-COV1901				Group B: Three Prior Doses of MVC-COV1901			
	MVC-COV1901 (15 mcg) (N = 15), n (%)	MVC-COV1901 (15 mcg, Beta) (N = 15), n (%)	MVC-COV1901 (25 mcg, Beta) (N = 15), n (%)	All Participants (N = 45), n (%)	MVC-COV1901 (15 mcg) (N = 21), n (%)	MVC-COV1901 (15 mcg, Beta) (N = 21), n (%)	MVC-COV1901 (25 mcg, Beta) (N = 20), n (%)	All Participants (N = 62), n (%)
Any Solicited Systemic AEs	9 (60.0)	9 (60.0)	9 (60.0)	27 (60.0)	9 (42.9)	7 (33.3)	13 (65.0)	29 (46.8)
Grade 1	7 (46.7)	8 (53.3)	6 (40.0)	21 (46.7)	7 (33.3)	6 (28.6)	12 (60.0)	25 (40.3)
Grade 2	1 (6.7)	1 (6.7)	2 (13.3)	4 (8.9)	2 (9.5)	1 (4.8)	0	3 (4.8)
Grade 3	1 (6.7)	0	1 (6.7)	2 (4.4)	0	0	1 (5.0)	1 (1.6)
Fever	1 (6.7)	0	1 (6.7)	2 (4.4)	0	0	1 (5.0)	1 (1.6)
Grade 1	1 (6.7)	0	1 (6.7)	2 (4.4)	0	0	0	0
Grade 2	0	0	0	0	0	0	1 (5.0)	1 (1.6)
Grade 3	0	0	0	0	0	0	0	0
Malaise/Fatigue	5 (33.3)	7 (46.7)	8 (53.3)	20 (44.4)	7 (33.3)	6 (28.6)	8 (40.0)	21 (33.9)
Grade 1	3 (20.0)	7 (46.7)	5 (33.3)	15 (33.3)	5 (23.8)	5 (23.8)	7 (35.0)	17 (27.4)
Grade 2	1 (6.7)	0	2 (13.3)	3 (6.7)	2 (9.5)	1 (4.8)	0	3 (4.8)
Grade 3	1 (6.7)	0	1 (6.7)	2 (4.4)	0	0	1 (5.0)	1 (1.6)
Myalgia	4 (26.7)	3 (20.0)	5 (33.3)	12 (26.7)	5 (23.8)	1 (4.8)	7 (35.0)	13 (21.0)
Grade 1	3 (20.0)	2 (13.3)	4 (26.7)	9 (20.0)	5 (23.8)	1 (4.8)	7 (35.0)	13 (21.0)
Grade 2	1 (6.7)	1 (6.7)	1 (6.7)	3 (6.7)	0	0	0	0
Grade 3	0	0	0	0	0	0	0	0
Headache	5 (33.3)	2 (13.3)	4 (26.7)	11 (24.4)	3 (14.3)	3 (14.3)	4 (20.0)	10 (16.1)
Grade 1	4 (26.7)	2 (13.3)	3 (20.0)	9 (20.0)	3 (14.3)	3 (14.3)	3 (15.0)	9 (14.5)

	Group A: Two Prior Doses of MVC-COV1901				Group B: Three Prior Doses of MVC-COV1901			
	MVC-COV1901 (15 mcg) (N = 15), n (%)	MVC-COV1901 (15 mcg, Beta) (N = 15), n (%)	MVC-COV1901 (25 mcg, Beta) (N = 15), n (%)	All Participants (N = 45), n (%)	MVC-COV1901 (15 mcg) (N = 21), n (%)	MVC-COV1901 (15 mcg, Beta) (N = 21), n (%)	MVC-COV1901 (25 mcg, Beta) (N = 20), n (%)	All Participants (N = 62), n (%)
Grade 2	1 (6.7)	0	1 (6.7)	2 (4.4)	0	0	1 (5.0)	1 (1.6)
Grade 3	0	0	0	0	0	0	0	0
Nausea/Vomiting	2 (13.3)	1 (6.7)	2 (13.3)	5 (11.1)	0	0	1 (5.0)	1 (1.6)
Grade 1	1 (6.7)	1 (6.7)	2 (13.3)	4 (8.9)	0	0	1 (5.0)	1 (1.6)
Grade 2	1 (6.7)	0	0	1 (2.2)	0	0	0	0
Grade 3	0	0	0	0	0	0	0	0
Diarrhea	5 (33.3)	1 (6.7)	2 (13.3)	8 (17.8)	1 (4.8)	3 (14.3)	5 (25.0)	9 (14.5)
Grade 1	4 (26.7)	1 (6.7)	2 (13.3)	7 (15.6)	1 (4.8)	2 (9.5)	5 (25.0)	8 (12.9)
Grade 2	0	0	0	0	0	1 (4.8)	0	1 (1.6)
Grade 3	1 (6.7)	0	0	1 (2.2)	0	0	0	0

Abbreviations: N = number of subjects in the population; n = number of subjects in the specific category. % = percentage of subjects with N as the denominator.

Table S3. Summary of Unsolicited Adverse Events and Other Adverse Events

	Group A: Two Prior Doses of MVC-COV1901				Group B: Three Prior Doses of MVC-COV1901			
	MVC-COV1901 (15 mcg) (N = 15), n (%)	MVC-COV1901 (15 mcg, Beta) (N = 15), n (%)	MVC-COV1901 (25 mcg, Beta) (N = 15), n (%)	All Participants (N = 45), n (%)	MVC-COV1901 (15 mcg) (N = 21), n (%)	MVC-COV1901 (15 mcg, Beta) (N = 21), n (%)	MVC-COV1901 (25 mcg, Beta) (N = 20), n (%)	All Participants (N = 62), n (%)
Unsolicited AEs	4 (26.7)	6 (40.0)	5 (33.3)	15 (33.3)	6 (28.6)	8 (38.1)	3 (15.0)	17 (27.4)
Related Unsolicited AEs	1 (6.7)	1 (6.7)	2 (13.3)	4 (8.9)	2 (9.5)	2 (9.5)	2 (10.0)	6 (9.7)
Unsolicited AEs ≥ Grade 3	0	0	0	0	0	0	0	0
Related Unsolicited AEs ≥ Grade 3	0	0	0	0	0	0	0	0
AEs ≥ Grade 3	0	0	0	0	0	0	0	0
Related AEs ≥ Grade 3	0	0	0	0	0	0	0	0
SAEs	0	0	0	0	0	0	0	0
Related SAEs	0	0	0	0	0	0	0	0
AESI (including pIMD)	0	0	0	0	0	0	0	0
VAED	0	0	0	0	0	0	0	0
AEs Leading to Intervention Discontinuation	0	0	0	0	0	0	0	0
AEs Leading to Study Withdrawal	0	0	0	0	0	0	0	0
Death	0	0	0	0	0	0	0	0

Abbreviations: N = number of subjects in the population; n = number of subjects with events; AE = Adverse Event; SAE = Serious Adverse Event; AESI = Adverse events of special interest; pIMD = potential immune mediated disorders; VAED = Vaccine-associated enhanced disease.

Table S4. Summary of immunogenicity data for Groups A and B

		Group A					
		MVC-COV1901 (15 mcg) (n=14)		MVC-COV1901-Beta (15 mcg) (n=12)		MVC-COV1901-Beta (25 mcg) (n=12)	
		[GMT]	95% CI	[GMT]	95% CI	[GMT]	95% CI
WT (NT ₅₀)*	V2 (Day 1)	61.28	(34.48, 108.91)	50.74	(27.26, 94.44)	42.47	(22.82, 79.03)
	V5 (Day 29)	1352.00	(797.38, 2292.40)	1805.02	(1023.61, 3182.94)	3602.75	(2036.68, 6373.05)
WT GMT ratio**	V5/V2	26.29	(15.51, 44.58)	35.10	(19.91, 61.90)	70.06	(39.61, 123.94)
Beta (NT ₅₀)*	V2 (Day 1)	9.75	(5.57, 17.08)	6.29	(3.43, 11.52)	5.99	(3.27, 10.98)
	V5 (Day 29)	225.59	(128.13, 397.17)	931.34	(509.33, 1703.00)	1476.85	(806.39, 2704.76)
Beta GMT ratio**	V5/V2	30.98	(17.60, 54.55)	127.92	(69.96, 233.91)	202.85	(110.76, 371.51)
Anti-spike IgG (WT)	V2 (Day 1)	1384.95	(876.59, 2188.12)	1301.00	(793.82, 2132.21)	1073.76	(655.17, 1759.79)
	V4 (Day 15)	25878.60	(17387.24, 38516.84)	32938.41	(21459.28, 50558.02)	43208.61	(28085.34, 66475.38)
	V5 (Day 29)	25257.76	(16360.67, 38993.18)	30672.19	(19210.70, 48971.84)	61907.00	(38676.11, 99091.57)
IgG GMT ratio**	V4/V2	20.65	(13.88, 30.74)	26.29	(17.13, 40.35)	34.48	(22.41, 53.05)
	V5/V2	20.16	(13.06, 31.12)	24.48	(15.33, 39.08)	49.41	(30.87, 79.08)
Pseudovirus NT ID ₅₀ (WT)	V2 (Day 1)	45.12	(98.07, 20.76)	35.97	(19.84, 65.21)	40.62	(26.33, 62.66)
	V4 (Day 15)	1520.96	(1023.93, 2259.24)	1723.40	(1227.59, 2419.44)	2315.39	(1879.03, 2853.08)
Pseudovirus NT ID ₅₀ (BA.4/BA.5)	V2 (Day 1)	14.50	(9.39, 22.38)	10.00	(10.00, 10.00)	10.93	(8.99, 13.30)
	V4 (Day 15)	139.11	(76.16, 254.09)	240.10	(137.63, 418.86)	425.65	(272.79, 664.17)
Pseudovirus NT ID ₉₀ (WT)	V2 (Day 1)	18.53	(10.30, 33.33)	14.58	(10.82, 19.63)	14.05	(10.02, 19.68)
	V4 (Day 15)	434.71	(267.37, 706.78)	558.18	(328.24, 949.20)	888.27	(551.22, 1431.43)
Pseudovirus NT ID ₉₀ (BA.4/BA.5)	V2 (Day 1)	11.58	(9.33, 14.38)	10.00	(10.00, 10.00)	10.00	(10.00, 10.00)
	V4 (Day 15)	54.52	(30.41, 97.75)	92.95	(57.80, 149.50)	157.99	(105.15, 237.39)

		Group B					
		MVC-COV1901 (15 mcg) (n=17)		MVC-COV1901-Beta (15 mcg) (n=18)		MVC-COV1901-Beta (25 mcg) (n=18)	
		[GMT]	95% CI	[GMT]	95% CI	[GMT]	95% CI
WT (NT50)*	V2 (Day 1)	292.89	(220.46, 389.11)	253.89	(192.56, 334.76)	263.29	(198.18, 349.79)
	V5 (Day 29)	867.93	(629.98, 1195.74)	1124.98	(824.29, 1535.36)	928.54	(680.78, 1266.48)
WT GMT ratio**	V5/V2	3.25	(2.36, 4.47)	4.21	(3.08, 5.74)	3.47	(2.55, 4.74)
Beta (NT50)*	V2 (Day 1)	34.02	(21.76, 53.19)	25.09	(16.24, 38.77)	31.17	(19.94, 48.74)
	V5 (Day 29)	147.14	(102.32, 211.61)	459.23	(322.19, 654.56)	323.78	(227.68, 460.43)
Beta GMT ratio**	V5/V2	5.03	(3.49, 7.23)	15.69	(11.01, 22.36)	11.06	(7.78, 15.73)
Anti-spike IgG (WT)	V2 (Day 1)	6712.17	(5261.78, 8562.35)	4620.77	(3645.90, 5856.32)	5307.28	(4160.46, 6770.21)
	V4 (Day 15)	21078.01	(15675.17, 28343.06)	28179.38	(21170.75, 37508.24)	21638.16	(16216.34, 28872.72)
	V5 (Day 29)	19014.66	(14364.79, 25169.70)	24953.2	(19040.94, 32701.23)	21889.96	(16782.37, 28552.02)
IgG GMT ratio**	V4/V2	3.86	(2.87, 5.19)	5.16	(3.87, 6.87)	3.96	(2.97, 5.28)
	V5/V2	3.48	(2.63, 4.61)	4.57	(3.49, 5.99)	4.01	(3.07, 5.23)
Pseudovirus NT ID50 (WT)	V2 (Day 1)	611.33	(400.87, 932.27)	388.14	(271.86, 554.15)	408.18	(254.72, 654.10)
	V4 (Day 15)	1831.75	(1449.69, 2314.49)	1919.17	(1595.53, 2308.44)	1919.51	(1613.19, 2284.00)
Pseudovirus NT ID50 (BA.4/BA.5)	V2 (Day 1)	33.28	(23.69, 46.76)	22.31	(15.16, 32.83)	25.66	(19.46, 33.84)
	V4 (Day 15)	136.83	(93.16, 200.95)	222.44	(135.10, 366.22)	154.62	(109.03, 219.28)
Pseudovirus NT ID90 (WT)	V2 (Day 1)	108.97	(82.54, 143.87)	81.60	(60.18, 110.66)	92.07	(64.51, 131.40)
	V4 (Day 15)	428.68	(308.92, 594.85)	533.7	(360.77, 789.53)	417.94	(328.33, 532.01)
Pseudovirus NT ID90 (BA.4/BA.5)	V2 (Day 1)	11.85	(9.69, 14.50)	11.46	(9.80, 13.42)	11.35	(9.82, 13.12)
	V4 (Day 15)	50.83	(35.40, 72.98)	84.52	(55.02, 129.83)	63.74	(46.65, 87.10)

*NT50 GMT and corresponding CI are calculated using an ANCOVA model with baseline log-titers, BMI (<30 or >=30 kg/m²) and comorbidity (yes or no) and sex (male or female) as covariate.

**IU/mL was converted from NT50 GMT with the following formula: $Y = 1.4663 \cdot (X^{0.8729})$, where X = titer in NT50 GMT and Y = titer in IU/mL